Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Australian researchers have developed a powerful new way to target deadly, drug-resistant bacteria by designing antibodies ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.

Discover the potential of lab-made antibodies in targeting drug-resistant bacteria and fighting hospital-acquired infections.

Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...